The largest database of trusted experimental protocols

Ova peptide 323 339

Manufactured by GenScript
Sourced in United States

OVA peptide 323–339 is a synthetic peptide derived from the chicken ovalbumin protein. It consists of the amino acid sequence from position 323 to 339 of the ovalbumin molecule. This peptide can be used in research applications, but its specific functions and intended uses should not be extrapolated beyond the provided factual information.

Automatically generated - may contain errors

5 protocols using ova peptide 323 339

1

BMDC-Mediated CD4+ T Cell Activation

Check if the same lab product or an alternative is used in the 5 most similar protocols
BMDCs were prepared as previously described and purified by CD11c+ magnetic beads. BMDCs were co-cultured with isolated OT-II naïve CD4+ T cells at a 1:10 ratio in complete RPMI in 96-well V-bottom plates. Cells were harvested 3 days later for further analysis. OVA peptide 323-339 (GenScript, USA) was added to wells at 1 mg/mL as a positive control.
+ Open protocol
+ Expand
2

FMNL1 Regulates CD8+ and CD4+ T Cell-Mediated Diabetes

Check if the same lab product or an alternative is used in the 5 most similar protocols
WT and FMNL1 KO CD8+ OT-I T cells were activated ex vivo with OVA peptide 257–264 (Pi Proteomics) for 2 days in the presence of irradiated CD45.1/.1 splenocytes and then cultured with IL-2 as above for 4 days. WT and FMNL1 KO CD4+ OT-II T cells were activated with OVA peptide 323–339 (GenScript) for 2 days in the presence irradiated CD45.1/.1 splenocytes and then cultured with IL-2 as above for 4 days. On day 6 post-antigen stimulus, dead cells were removed by Histopacque-1119 (Millipore Sigma) density gradient. OT-I (5 × 106) and OT-II (2.5 × 106) T cells of the same FMNL1 genotype (WT with WT, KO with KO) were then combined and transferred i.v. into RIP-mOVA recipient mice. The blood glucose of the recipient mice was then monitored daily from day 4–28 post-transfer. Mice with blood glucose levels of greater than 350 mg/dL on two consecutive days were considered to be diabetic and were euthanized.
+ Open protocol
+ Expand
3

Induction of Th2 Cells and Adoptive Transfer

Check if the same lab product or an alternative is used in the 5 most similar protocols
Antigen presenting cells (APC) were prepared from CD4 T cell-depleted splenocytes and lymphocytes and pretreated with mitomycin C (Calbiochem) for 20 mins at 37°C. RPMI 1640 medium was supplemented with 10% FBS, 1 mM sodium pyruvate, 10 mM HEPES buffer, 100 U/ml penicillin, 100 μg/ml streptomycin, and 50 μM 2-ME. To induce Th2 T cells, the naïve DO11.10 T cells were stimulated with 5μg/ml OVA peptide (323–339) (GenScript) plus APCs (naïve CD4+CD62L+T cell: APC=1:5.5) under Th2 conditions (20 ng/ml rmIL-4, 1 ug/ml anti-mouse IFN-γ, 2 ug/ml anti-mouse IL-12, 0.5 ug/ml anti-mouse CD28) for 5 consecutive days in vitro.
20 × 106 in vitro differentiated Th2 cells were adoptively transferred to recipient mice via tail intravenous (iv) injection. The presence of donor cells in peripheral blood was monitored weekly by CD4 and KJ1.26 staining and flow cytometry. At the end of monitoring period, the recipient mice were challenged intranasally with 100 μg OVA in 40 μl PBS for 3 days. Mice were euthanized 24 h after the last challenge for further analysis.
+ Open protocol
+ Expand
4

Isolation and Co-culture of Immune Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Primary cells were isolated by mechanical disruption of cell suspensions of spleen (and also lymph nodes in the case of CD4+ T‐cell isolation). B cells from DICER‐KO and C57/BL6 wild‐type mice were isolated by immunomagnetic depletion with anti‐CD43 beads (Miltenyi). During the 24 h before co‐culture, isolated B cells were cultured in EV‐depleted complete RPMI medium [EV‐free RPMI supplemented with 10% EV‐depleted fetal bovine serum (discarding the pellet after ultracentrifugation for 16 h at 100,000 g), 50 μM β‐mercaptoethanol (Invitrogen), 10 mM Hepes (Invitrogen), and antibiotics]. The same batch of ultracentrifuged EV‐depleted serum was used for all experiments to minimize variability and checked by NanoSight for EV depletion. For B‐cell pre‐activation, this medium was supplemented either with 25 μg/ml LPS (Sigma) and 10 ng/ml IL‐4 (Peprotech) or with 10 μg/ml CD40 and 10 μg/ml F(ab)’2 fragments of goat anti‐mouse IgM (Jackson Immunoresearch). Regardless of the activation method, the B cells were incubated in the presence or absence of 5 μg/ml OVA peptide 323–339 (GenScript). For OT‐II‐derived CD4+ T‐cell isolation, splenocytes and lymph node cells were incubated for 16 h in EXO‐free RPMI medium supplemented with 5 μg/ml of OVA, and T cells were then purified using the CD4+ T‐cell isolation kit (Miltenyi Biotec). Antibodies and primers are listed in Appendix Table S2.
+ Open protocol
+ Expand
5

CD4+ T Cell Activation Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD4+ T cells were isolated from the spleens of C57BL/6J as described and stimulated with the indicated concentrations of anti-CD3ε and 1 μg/ml of anti-CD28 (BD Pharmingen) for 48 h. Cells were analyzed by flow cytometry and IL-2 was detected in the supernatants by an ELISA. For co-culture experiments, empty vector Chinese Hamster Ovary – Antigen-presenting cells (CHO-APCs) were fixed by treating with Mitomycin C (Sigma) 37°C for 45 min 6 × 105 cells/ml of CHO-APCs were pulsed with the indicated concentrations of ova-peptide 323–339 (Genscript). CD4+ T cells were isolated from spleens of BALB/c-Tg(DO11.10)10Loh/J and mixed with peptide pulsed APCs at 2.5 × 106 cells/ml in each well of a 12-well plate. Cells were harvested after 48 h and analyzed by flow cytometry after gating on CD4+ T cells expressing the DO.11.10-TCR. Supernatants were used for detection of IL-2 by an ELISA.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!